Increasing evidence points to a role for the immune system in the regulation of metabolism. Two new studies in mice indicate treatment with interleukin-22 restores mucosal immunity in diabetes and alleviates metabolic disease, resulting in improved glycemic control.
References
Donath, M.Y. Nat. Rev. Drug Discov. 13, 465–476 (2014).
Hasnain, S.Z. et al. Nat. Med. 20, doi:10.1038/nm.3705 (2 November 2014).
Wang, X. et al. Nature 514, 237–241 (2014).
Cani, P.D., Geurts, L., Matamoros, S., Plovier, H. & Duparc, T. Diabetes Metab. 40, 246–257 (2014).
Tremaroli, V. & Backhed, F. Nature 489, 242–249 (2012).
Colonna, M. Immunity 31, 15–23 (2009).
Maedler, K. et al. J. Clin. Invest. 110, 851–860 (2002).
Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Nat. Immunol. 11, 136–140 (2010).
Sabat, R., Ouyang, W. & Wolk, K. Nat. Rev. Drug Discov. 13, 21–38 (2014).
Winer, S. et al. Nat. Med. 15, 921–929 (2009).
Dalmas, E. et al. Diabetes 63, 1966–1977 (2014).
Fabbrini, E. et al. Gastroenterology 145, 366–374. e1–e3 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Dalmas, E., Donath, M. A role for interleukin-22 in the alleviation of metabolic syndrome. Nat Med 20, 1379–1381 (2014). https://doi.org/10.1038/nm.3748
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3748
- Springer Nature America, Inc.
This article is cited by
-
Interlukin-22 improves ovarian function in polycystic ovary syndrome independent of metabolic regulation: a mouse-based experimental study
Journal of Ovarian Research (2024)
-
Opportunities and challenges: interleukin-22 comprehensively regulates polycystic ovary syndrome from metabolic and immune aspects
Journal of Ovarian Research (2023)
-
Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study
Cardiovascular Diabetology (2017)
-
Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation
Cell Death & Disease (2017)
-
Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences
Cell & Bioscience (2015)